MA S2035

Eliminates the state tax deduction for pharmaceutical companies' direct-to-consumer advertising expenses for prescription drugs and devices marketed to Massachusetts patients

Covers all direct and indirect advertising costs including media advertising, coupons, outreach programs, persistency programs, and any marketing directed at consumers rather than licensed prescribers

For national or regional advertising campaigns, disallows the proportional share of expenses attributable to Massachusetts residents

Amends Chapter 63 of the General Laws by adding a new exclusion to the definition of "net income" for corporate tax purposes

Sponsored by Senator Jason M. Lewis (Fifth Middlesex) with co-sponsor Senator Rebecca L. Rausch; similar legislation was filed in the 2023-2024 session